Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Cell nucleus may play role in enabling cells to evade crowded environments

Cell nucleus may play role in enabling cells to evade crowded environments

Moffitt study uncovers how specific molecules promote cancer progression

Moffitt study uncovers how specific molecules promote cancer progression

Two studies show the benefit of collaborative research on childhood blood disorders

Two studies show the benefit of collaborative research on childhood blood disorders

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

Researchers are developing a new class of compounds against various cancers

Researchers are developing a new class of compounds against various cancers

CAR NKT cells offer a promising approach to combat hard-to-treat solid tumors

CAR NKT cells offer a promising approach to combat hard-to-treat solid tumors

Scientists develop new type of precise therapeutic vaccine against leukemia

Scientists develop new type of precise therapeutic vaccine against leukemia

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

Proteolytic activation of the SARS-CoV-2 spike S1/S2 site

Proteolytic activation of the SARS-CoV-2 spike S1/S2 site

ACGT awards $500,000 grant to advance strategies for treating solid tumors

ACGT awards $500,000 grant to advance strategies for treating solid tumors

New approach transforms oldest antibiotics into safer, stronger drugs

New approach transforms oldest antibiotics into safer, stronger drugs

$9.1 million NCI grant renewal will support researchers studying retrovirus cancer models

$9.1 million NCI grant renewal will support researchers studying retrovirus cancer models

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Researchers identify a potential target for small cell lung cancer

Researchers identify a potential target for small cell lung cancer

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Blocking nuclear pore complex formation can help selectively kill cancer cells

Blocking nuclear pore complex formation can help selectively kill cancer cells

NCCN publishes new clinical practice guidelines for pediatric Hodgkin lymphoma

NCCN publishes new clinical practice guidelines for pediatric Hodgkin lymphoma

Marrowquant can quantify multiple bone components in histological images

Marrowquant can quantify multiple bone components in histological images

Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

Challenges in High Complexity Flow Cytometry

Challenges in High Complexity Flow Cytometry

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.